All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-11-11T14:24:23.000Z

Is CNS prophylaxis warranted in DLBCL?

By Ellen Jenner, Kreena Mistry, Jack Ladhams
Featured
Matthew Wilson
Nov 11, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in DLBCL.

Bookmark this article

During the COLYM 2022 Annual Meeting, the Lymphoma Hub spoke with Matthew Wilson, Beatson West of Scotland Cancer Centre, Glasgow, UK. We asked, Is central nervous system (CNS) prophylaxis warranted in DLBCL?

Is CNS prophylaxis warranted in DLBCL?

Wilson discusses the topic of CNS relapse in DLBCL and explains that there is a lack of data in support of a clear prophylactic treatment strategy. Wilson summarizes the latest data for the use of high-dose methotrexate and describes how it is may be used sparingly. Advancements in novel molecular techniques to screen patients at baseline for CNS disease hold great promise for guiding future prophylactic treatment regimens.

More about...
Aggressive B-cell lymphomasCOLYM 2022Diffuse large B-cell lymphomaMethotrexate

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Lenalidomide and rituximab combination for R/R PCNSL-DLBCL patients

This open-label, multicenter, singe-arm, prospective, phase II trial the efficacy of rituximab together with lenalidomide was assessed in DLBCL-PCNS patients.

Feb 15, 2019
Add bookmark

Lenalidomide and rituximab combination for R/R PCNSL-DLBCL patients

This open-label, multicenter, singe-arm, prospective, phase II trial the efficacy of rituximab together with lenalidomide was...

Feb 15, 2019
Add bookmark

Published case study – First case of DLBCL presenting as bilateral internal auditory canal lesions and mimicking bilateral schwannomas

Last month, in a Letter to the Editor of the Canadian Journal of Neurological Sciences, Nevena Markovic from...

Oct 16, 2017
Add bookmark

Published case study – First case of DLBCL presenting as bilateral internal auditory canal lesions and mimicking bilateral schwannomas

Last month, in a Letter to the Editor of the Canadian Journal of...

Oct 16, 2017

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox